Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Indicia Production Acquires Biotechnologie Appliquee

Published: Friday, March 22, 2013
Last Updated: Thursday, March 21, 2013
Bookmark and Share
The acquisition strengthens Indicia Production’s ability to subcontract the manufacture of ready-to-use media for microbiological testing.

Indicia Production has announced the acquisition of Biotechnologie Appliquee, based in Taden, in Cotes-d’Armor, France.

The financial terms of this buyout, completed at the end of February, have not been disclosed.

Biotechnologie Appliquee, with a turnover of EUR 500,000 in 2012 and four employees, provides contract manufacturing of ready-to-use media for microbiological testing to the food-processing, pharmaceutical and cosmetic industries.

The company is smaller and more flexible than Indicia Production with extensive expertise in subcontracting. It primarily provides low-volume manufacturing.

This acquisition therefore complements the range of mass-manufactured products from Indicia Production in Lyon.

Indicia Production can now provide contract services for both high and low volume manufacturing and can also respond to client requirements more quickly.

Indicia plans to secure new clients by expanding and diversifying its product range. The company also aims to draw on Biotechnologie Appliquee’s expertise to develop new products throughout 2013.

Ready-to-use culture media are used in the pharmaceutical industry as well as for microbiological diagnostics in food processing and environmental and water monitoring.

They are made from high-quality raw materials and use dehydrated bases selected in accordance with various standards. They are manufactured using advanced technology and are subject to quality testing by approved microbiologists.

“By joining with Indicia, we are able to expand our client base and offer a wider range of products,” said Jean-Yves Horvais, director of Biotechnologie Appliquee.

Horvais continued, “In return, Indicia brings its mass-manufacturing capacities and structured quality assurance. This will allow us to attract new companies within the industry.”

The acquisition enables Indicia Production to strengthen its position as a European leader in the manufacturing of ready-to-use media for microbiological testing.

Indicia is the first subcontractor to manufacture media pouches. The concept was developed at the site 15 years ago.

Biotechnologie Appliquee provides the newly formed company with a better understanding of the raw materials used in these media.

“With this acquisition, we hope to strengthen our production capacities and our subcontracting qualities for both high and low volume manufacturing,” said Stephane Legastelois, president and CEO of Indicia Production.

This buyout is part of Indicia Production’s growth strategy, which began in 2010, including the acquisition of new technologies to increase capacities for filling and sterilizing company media pouches.

Indicia Production, whose turnover reached EUR 5.1 million in 2012, expects a significant increase in profits over the next five years.

“The contract manufacturing market for microbiological testing and aseptic filling is booming. More industry professionals are now choosing to outsource these services in order to reduce their fixed costs,” said Stephane Legastelois. “They are also showing a keen interest in contract services, which we have just strengthened with this acquisition.”

A department manager is expected to join Indicia Production’s on-site team at Biotechnologie Appliquee, in Taden, in the second quarter of 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!